Dr. Andy Herbert and Richard Boyd developed the Scottish start-up company Invizius, which uses its unique H-Guard® Priming Solution to lessen the harmful inflammatory effects that dialysis and cardiopulmonary bypass have on patients.
Invizius thinks that by applying the solution to extra-corporeal devices like a dialysis filter, patients’ blood could enter the device undetected and therefore reduce the inflammatory response.
The company is heading its Series A funding round in 2020 and has secured investments from Mercia, Solvay, Downing, Old College Capital, and the Scottish Investment Bank.
